OS Therapies Inc (OSTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Research & development | 2,499,498 | |||
| General & administrative | 2,339,230 | |||
| Loss from operations | -4,838,728 | |||
| Interest income | 64 | |||
| Interest expense | - | |||
| Change in fair value of warrant liability | -302,042 | |||
| Total other income/expense | 302,106 | |||
| Net loss | -4,536,622 | |||
| Cumulative series a preferred stock dividend requirement | - | |||
| Net loss available to common shareholders | -4,536,622 | |||
| Basic loss per common share outstanding (in dollars per share) | -0.19 | |||
| Diluted loss per common share outstanding (in dollars per share) | -0.19 | |||
| Weighted average of shares (in shares) | 25,114,460 | |||